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type on postoperative embolization
Paul D. Hayes, FRCS,a Holger Allroggen, MD,b Sarah Steel, BSc,a Matthew M. Thompson, MD,
FRCS,a Nicholas J. M. London, MD, FRCS,a Peter R. F. Bell, MD, FRCS,a and A. Ross Naylor, MD,
FRCS,a Leicester, United Kingdom
Purpose: A recent overview indicated that although routine patching is safer than routine primary closure after carotid
endarterectomy (CEA), there is no systematic evidence that patch type influences outcome. However, most surgeons
still believe that prosthetic patches are probably more thrombogenic than vein patches. This study tested the hypothe-
sis that there was no difference in thrombogenicity between the different patch types.
Methods: A total of 274 patients undergoing 276 CEAs were randomized to either Dacron-patch closure (n = 137) or
vein-patch closure (n = 139). All patients with an accessible cranial window were monitored for 3 hours postoperatively
with transcranial Doppler scanning (TCD). The number of emboli and rate of embolization were quantified with the
requirement for selective dextran therapy to control high rates of postoperative embolization. All patients were assessed
postoperatively and again at 30 days by a neurologist, and all patients underwent a duplex examination at 30 days.
Results: The 30-day death/any stroke rate was 2.2% for patients in the Dacron-patch group and 3.6% for patients in
the vein-patch group (P = .72). Patients in the Dacron-patch group had a higher incidence of postoperative emboli
(median, 5; interquartile range, 0-10.5) than patients in the vein-patch group (median, 3; interquartile range, 1-17; P
= .028). However, the incidence of detecting more than 50 emboli was virtually identical, and patch type had no effect
on the incidence of high-rate, sustained embolization that required dextran therapy (5.3% for Dacron, 3.7% for vein).
No patient had a carotid thrombosis at 30 days.
Conclusion: Sustained, high-rate embolization, previously shown to be highly predictive of progression to carotid
thrombosis, appears to be patient dependent, rather than related to patch type. (J Vasc Surg 2001;33:994-1000.)
A recent overview of the randomized trials of closure
during carotid endarterectomy (CEA) suggested that a
policy of routine patching was safer than a policy of rou-
tine primary closure because of a threefold reduction in
perioperative thrombosis, early and late stroke, and late
restenosis.1 There is, however, no consensus on the opti-
mal material to be used for patching. The principal advan-
tages of vein include no cost, use of autogenous tissue,
resistance to infection, and ease of handling. Dis-
advantages include harvest site complications and vein-
patch rupture (which is reduced by harvesting the vein
from the groin, but then the full length of vein is unavail-
able for future use). The advantages of prosthetic patches
include immediate availability, no harvest-site complica-
tions, the avoidance of rupture, and preservation of the
saphenous vein. Its principal disadvantage is infection.
Although no significant difference in outcome between
patch types was suggested by means of the meta-analysis,
a perception remains among surgeons that prosthetic
patches are probably more thrombogenic than vein
patches.
Recent work from this unit has shown that as many as
70% of patients will have one or more emboli detected in
the first 3 postoperative hours after CEA .2 However, only
about 5% of patients will have sustained, high-rate
embolization, which has now been shown to be highly
predictive of progression to carotid thrombosis and
stroke.3-7 When reexamined, these patients are found to
have friable platelet thrombus adherent to the endarterec-
tomy zone, usually with no evidence of any underlying
technical error.8 The current study was, therefore, specifi-
cally designed to quantify rates of postoperative emboliza-
tion as an indicator of prothrombotic potential in a
prospective, randomized trial of vein versus Dacron
patches in patients undergoing CEA.
MATERIALS AND METHODS
The trial was approved by the Leicestershire Area
Ethics Committee, and patients gave informed consent. A
total of 294 patients undergoing CEA between December
1, 1997, and December 31, 1999, were considered for
inclusion; 20 patients were subsequently excluded because
of their refusal to give informed consent (n = 10), bilateral
varicose vein surgery (n = 6), osteomyelitis (n = 1), severe
claudication (n = 1), redo CEA (n = 1), and combined
common carotid angioplasty plus CEA (n = 1). Therefore,
274 patients were randomized and underwent 276 CEAs.
This paper details outcome, rate of embolization, and
duplex findings at 30 days.
Randomization method. Three hundred computer-
generated, random treatment methods (vein patch or
Dacron patch) were consecutively numbered and sealed in
opaque envelopes and allocated on a consecutive basis
(immediately after induction of anesthesia), starting with
envelope 1.
Carotid endarterectomy. Antiplatelet therapy was
not stopped before surgery, and the patient’s usual med-
ication was administered on the morning of surgery. CEA
was performed by a consultant vascular surgeon (n = 154)
or supervised trainee (n = 122) with normotensive, nor-
mocarbic general anesthesia with loupe magnification, sys-
temic administration of heparin (5000 units), routine
shunting (Pruitt-Inahara, Ideas for Medicine, North
Clearwater, Fla), and routine tacking sutures to the distal
intimal step to prevent distal intimal dissection. Patients
who were randomized to the vein-patch group had a seg-
ment of long saphenous vein harvested from the groin and
anastomosed with 6:0 prolene suture (Ethicon Ltd,
Somerville, NJ). Patients randomized to the Dacron-patch
group had a Hemashield Finesse patch (Boston Scientific
Ltd, St Albans, UK) inserted with 6:0 prolene suture
(Ethicon). The vein patch was simply used at the width
that it was when harvested (ie, the circumference of the
vein); it was not trimmed to size. The Dacron patch was a
standard 7 mm in width.
Blood flow velocity in the middle cerebral artery
(MCA) was monitored throughout the procedure with a
2-MHz pulsed wave TCD ultrasound scanner, a SciMed
PC2-64B, with a fixed-head probe system (Scimed UK,
Bristol, UK) protected by a semicircular metal headguard
with recording onto digital audiotape (DAT) for off-line
analysis of emboli.9,10 A 5-mm segment of the anastomo-
sis (adjacent to the orifice of the external carotid artery)
was left open. The shunt was removed, and the lumen was
vented and irrigated with heparinized saline. Before final
closure and restoration of flow, the lumen was inspected
with a flexible hysteroscope (Olympus 1070-48; Olympus,
Hamburg, Germany) to exclude residual luminal throm-
bus and intimal flaps.10
After the procedure, the patient was transferred to the
high dependency unit for further TCD monitoring. All
emboli detected in the first 3 postoperative hours were
recorded onto DAT tape and quantified off-line. Earlier
studies from this unit have shown that postoperative
emboli are exclusively particulate9 and that 3 hours of
monitoring is just as effective as 6 hours.11,12 Studies have
shown that sustained postoperative embolization is highly
predictive of progression to thrombosis and stroke3,7 and
that this phase can be abolished with an incremental infu-
sion of dextran.11,12 Accordingly, any patient who had 25
or more emboli in any 10-minute period or whose emboli
distorted the MCA waveform (suggesting they were large)
were given an incremental infusion of dextran 40. An ini-
tial bolus of 20 mL of 10% dextran 40 was administered,
followed by an infusion at a rate that began at 20 mL/h.
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If the embolization rate failed to settle, the infusion rate
was increased by 10 mL/h until embolization was con-
trolled. The number of emboli and rate of embolization
were quantified for every patient, as was the requirement
for dextran therapy.
Postoperative assessment. All patients were exam-
ined postoperatively by the same neurologist (H.A.), who
documented any new neurologic deficit or cranial nerve
injury. Any new neurologic deficit lasting more than 24
hours was classified as a stroke, and these patients were
investigated by means of a computed tomography
scan/autopsy, Duplex scanning assessment of the internal
carotid artery (ICA), and TCD assessment of the intracra-
nial vessels. The neurologist reassessed all trial patients at
30 days, whereas patients who sustained a perioperative
stroke underwent an assessment of the stroke severity with
the Oxfordshire Handicap Stroke Score (OHS).13 The
advantage of the OHS over the Rankin score is that it
takes into account the disability associated with dysphasia.
A minor (nondisabling) stroke scored 0 to 2 on the OHS
scale, whereas a disabling stroke scored 3 to 6. All patients
underwent a color duplex assessment of the operated
artery at 30 days by the same vascular technologist (S.S.)
with the ATL Ultramark (Bothel, Wash). Attention was
directed toward measuring the maximum diameter of the
carotid bulb, excluding carotid occlusion, and diagnosing
a stenosis ≥ 70%. At the time of discharge, each patient was
asked to complete a visual analog score (range, 1-5) for
pain in the groin and neck wounds.
Statistical analysis. Analysis was based on “intention
to treat.” Any patient randomized to receive a vein patch
who then underwent Dacron patching because the vein
was inadequate was analyzed on the basis of the original
randomization to a vein patch. Similarly, any patient who
had already been randomized in the trial and who subse-
quently required a contralateral CEA received the same
type of patch as allocated by the first randomization. The
data in this study were not normally distributed; therefore,
nonparametric tests were adopted. Continuous variables
were analyzed by using the Mann-Whitney U test.
Discrete variables were analyzed with the χ2 or Fisher
exact test, as appropriate. A P value less than .05 was
assumed to represent statistical significance.
RESULTS
Patient demographics. Three patients underwent
bilateral CEAs within the trial, and each received the same
Table I. Treatment changes after randomization
Dacron-patch Vein-patch
group group
No. of patients randomized 136 137
Bilateral patients receiving same patch 1 2
Total number of procedures 137 139
Carotid bypass grafting performed 3 2
ICA ligation 1 0
Unsuitable vein (Dacron patch inserted) 0 3
patch allocation to which they were randomized during the
first CEA. Table I summarizes the changes to treatment
after randomization. Five patients (1.8%) underwent
reversed saphenous vein bypass grafting procedures
because the ICA was either too thin after endarterectomy
(n = 2) or had pronounced distal coiling (n = 3), thereby
precluding safe patch closure. One patient (0.4%) under-
went carotid ligation because the distal ICA lumen was
narrow (2-3 mm) and had adherent mural (but not occlud-
ing) thrombus extending to the skull base on exploration.
MCA flow was indicated by means of TCD to be adequate
to tolerate carotid ligation. Finally, three patients (1.1%)
randomized to receive a vein patch received a Dacron patch
because no suitable vein was found after groin exploration.
Table II summarizes the preoperative patient demograph-
ics for the two groups, which were well matched for all
parameters. In particular, there was no significant differ-
ence in presentation, concurrent medical disease, the sever-
ity of the carotid disease, the time since the last cerebral
event, antiplatelet therapy, and dose of aspirin.
Table III details the 30-day perioperative data for
patch allocation. There was no significant difference in
length of operation, shunt and clamp times, patch length,
angioscopy findings, and neck drain losses. Because
patients randomized to receive a Dacron patch did not
have a groin wound, the overall drain losses were higher
for patients in the vein-patch group, and there was,
inevitably, a higher incidence of groin wound infections
(4.3%) and seromas/hematomas (3.6%) in patients in the
vein-patch group. There were no patch infections or rup-
tures in any patient in this study.
Postoperative outcome. Patch type did not influence
the requirement for treating early postoperative hyperten-
sion, transfusion requirements, early postoperative reex-
ploration for neck hematoma, and time to hospital dis-
charge (Table III). The median analog score for neck
wound pain was 2 (95% CI, 2.4-2.7) for the Dacron-patch
group and 2 (95% CI, 2.3-2.5) for the vein-patch group
(P = .15). The median analog score for groin-wound pain
was 1 (95% CI, 1.0-1.1) for the Dacron-patch group and
2 (95% CI, 2.1-2.4) for the vein-patch group (P < .0001).
Table IV summarizes the 30-day morbidity and mor-
tality rate data. The incidence of persisting cranial nerve
injury at 30 days (excluding the mandibular branch of the
facial nerve) was unrelated to patch type (3.6% for Dacron,
2.9% for vein; P = .78). No patient in either group recov-
ered from anesthesia with a new neurologic deficit. The
30-day death/disabling stroke rate was 1.5% for patients in
the Dacron-patch group and 2.9% for patients receiving a
vein patch. The death/any stroke rate was 2.2% for patients
in the Dacron-patch group and 3.6% for patients in the
vein-patch group. If the data are reanalyzed according to
which patch type the patients actually received in the trial
(ie, excluding vein bypass grafting procedures and correct-
ing for crossovers), the death/any stroke rate was 2.2% in
the 133 patients in the Dacron-patch group and 3.7% for
the 134 patients in the vein-patch group (P = .72).
All survivors underwent a color duplex scan of the
operated ICA at 30 days, and no patient in either group
was found to have a carotid occlusion or stenosis > 70%.
Four patients (2.9%) who were randomized to the
Dacron-patch group had a 30% to 69% stenosis detected
at 30 days, as compared with nine patients (6.5%) in the
vein-patch group (P = .26). The median carotid bulb
diameter at 30 days was 10.8 mm (95% CI, 10.3-10.8)
for patients in the Dacron-patch group and 12.0 mm
(95% CI, 11.9-12.6) for patients in the vein-patch group
(P = .001).
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Table II. Preoperative patient demographics
Dacron-patch group Vein-patch group
(n = 137) (n = 139) P value
Men:women 94:43 89:50 .48
Median age (y) 71 (95% CI, 67.3-70.2) 70 (95% CI, 68.9-71.5) .30
Treated hypertension 90 (66%) 91 (65%) 1.0
Earlier MI 26 (19%) 33 (24%) .45
Treated angina 39 (28%) 42 (30%) 1.0
Diabetes mellitus 22 (16%) 21 (15%) 1.0
Current smoker 37 (27%) 31 (22%) .40
No symptoms 15 (11%) 16 (12%) .9
TIA/amaurosis 82 (60%) 70 (50%) .12
Stroke 40 (29%) 53 (38%) .13
Unilateral > 70% stenosis 85 (62%) 91 (65%) .53
Bilateral > 70% stenosis 31 (23%) 24 (17%) .37
Stenosis and contralateral occlusion 21 (15%) 24 (17%) .75
Aspirin therapy alone 108 (79%) 101 (73%) .27
Median aspirin dose (mg) 75 (95% CI, 90-113) 75 (95% CI, 90-110) .91
Aspirin and dipyridamole 16 (12%) 25 (18%) .18
Dipyridamole therapy alone 4 (3%) 5 (4%) 1.0
Warfarin therapy alone 8 (6%) 8 (6%) 1.0
No antiplatelet/anticoagulant 1 (0.7%) 0 .97
MI, Myocardial infarction; TIA, transient ischemic attack.
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Postoperative embolization. Seven patients in the
Dacron-patch group (5.1%) and 12 patients in the vein-
patch group (8.6%) had no accessible cranial window for
TCD. The remaining patients underwent 3 hours of post-
operative TCD monitoring. Although the actual differ-
ence was small, patients randomized to the Dacron-patch
group had a significantly higher number of emboli
detected within the first 3 postoperative hours (median, 5;
interquartile range, 1-17) than the patients in the vein-
patch group (median, 3; interquartile range, 0-10.5; P =
.028). The Figure presents the frequency distribution of
emboli detected in the two groups of patients. Patients in
Table III. Perioperative patient demographics
Dacron-patch group Vein-patch group
(n =137) (n = 139) P value
Median operation time (min) 103 (95% CI, 102-114) 105 (95% CI, 102-115) .71
Median shunt time (min) 44 (95% CI, 43-51) 43 (95% CI, 42-48) .60
Median total clamp time (min) 7 (95% CI, 6.2-9.8) 7 (95% CI, 7.0-9.9) .38
Median patch length (cm) 6 (95% CI, 6.0-6.7) 5.8 (95% CI, 5.8-6.3) .10
Normal angioscopy results 124 (91%) 126 (91%) 1.0
Intimal flap repaired 3 (2%) 2 (1%) .68
Luminal thrombus removed 6 (4%) 8 (6%) .78
Median neck drain loss (mL) 40 (95% CI, 66-112) 40 (95% CI, 51-91) .038
Median groin drain loss (mL) 0 (95% CI, 0-1.4) 20 (95% CI, 22-42) .0001
Median total drain loss (mL) 40 (95% CI, 64-109) 60 (95% CI, 77-102) .058
Drainage of neck hematoma 10 (7%) 7 (5%) .43
Transfusion required 10 (7%) 9 (7%) .78
Postoperative hypertension 59 (43%) 53 (38%) .39
Median 3-h embolus count 5 (IQR, 1-17) 3 (IQR, 0-10.5) .028
Dextran administered 9 (6.6%) 7 (5%) .62
Median day of discharge 3 (95% CI, 2.7-3.3) 3 (95% CI, 2.7-3.3) .86
Superficial neck infection 2 (1.5%) 1 (0.7%) .99
Groin wound infection 0 6 (4%) .041
Groin seroma/hematoma 0 5 (4%) .074
Median carotid diameter (mm) 10.8 (95% CI, 10.3-10.8) 12.0 (95% CI, 11.9-12.6) .001
IQR, Interquartile range.
Frequency distribution of number of emboli detected in first 3 postoperative hours for patients random-
ized to receive Dacron patches and vein patches. Note that for high rates of embolization, curves overlap.
the Dacron-patch group had a tendency toward having
more emboli detected; however, above the threshold of 50
emboli, the two curves virtually overlapped. More impor-
tant, the presence of high-rate, sustained embolization
and the requirement for dextran therapy was unrelated to
patch type. Nine patients in the Dacron-patch group
(6.6%) required dextran therapy, as compared with seven
patients in the vein-patch group (5.0%; P = .62).
If the data are reanalyzed for the 133 patients who
actually received a Dacron patch in the trial, as compared
with the 134 who underwent vein patching (ie, excluding
bypass grafting procedures and crossovers), the basic data
remain unchanged. The median embolus count for
patients receiving a Dacron patch was five (interquartile
range, 1-17), as compared with three (interquartile range,
0-10.5) for patients receiving a vein patch (P = .027).
Seven patients (5.3%) who received a Dacron patch had
sustained embolization that required dextran therapy,
compared with six patients who received a vein patch
(4.4%; P = .78).
The causes of surgery-related strokes/deaths are
summarized in Table IV. Five of the eight deaths/
strokes (63%) followed cardiac events or intracranial
hemorrhage. The incidence of ipsilateral embolic stroke
was 0.7% for the whole series. No stroke in this trial fol-
lowed postoperative carotid thrombosis, and no patient
who was randomized to the vein-patch group sustained
an ipsilateral stroke caused by an MCA embolism.
However, two patients who were randomized to the
Dacron-patch group sustained focal embolic strokes
(sustained embolization on TCD, focal carotid territory
infarction on computed tomography scan). Severe car-
diac failure developed in one of these patients in the
immediate postoperative period, and reintubation and
inotropic support were required. High rates of
embolization were demonstrated by means of TCD, but
adequate doses of dextran could not be administered
because of the patient’s severe cardiac failure. He had a
disabling hemiparesis after extubation (OHS 3 at 30
days). The second patient had high rates of embolization
in the immediate postoperative period that were abol-
ished with dextran (0 emboli detected at 24 hours).
However, an upper-limb monoparesis developed on day
5. Profuse MCA embolization was again revealed by
means of TCD, and it was rapidly controlled with dex-
tran. His OHS score at 30 days was 1. When they under-
went scanning again at 30 days, neither of these patients
had duplex evidence of occlusion or a stenosis > 70%.
DISCUSSION
Meaningful interpretation of this study is dependent
on these assumptions: (1) the “high-intensity transients”
detected by means of TCD after CEA represent particu-
late emboli rather than gaseous elements or artifacts; (2)
sustained embolization is indicative of an increased risk of
thrombus formation within the endarterectomy zone; and
(3) emboli diagnosed by means of TCD are clinically rel-
evant.
“High-intensity transients” detected by means of
TCD were first reported during CEA in 1986,14 but there
was considerable skepticism about their nature and rele-
vance. Many clinicians assumed that they simply repre-
sented artifacts. Subsequent work has now clearly shown
that small embolic fragments can be detected by means of
TCD and that it is possible to differentiate emboli from
artifacts by using consensus criteria15 or dual-gated ultra-
sound scanning.16,17 Similarly, methods capable of differ-
entiating gaseous from solid elements have demonstrated
that emboli detected in the postoperative period are exclu-
sively particulate.9
A number of studies have reported that emboli
detected by means of TCD are associated with an increased
risk of adverse outcome. Embolization in patients with an
asymptomatic carotid stenosis is associated with an
increased risk of transient ischemic attack or stroke,18
whereas the risk of stroke after acute myocardial infarction
is significantly higher in patients with TCD evidence of
cerebral embolization.19 Patients with more than 10
emboli detected during the dissection phase of CEA have
a higher incidence of postoperative cognitive impairment20
and magnetic resonance imaging changes indicative of
ischemia,21 whereas excess intraoperative embolization has
been associated with an increased risk of operative
stroke.22 However, the most knowledge is currently
derived from studies on embolization in the early postop-
erative period after CEA. Evidence suggests that although
a policy of quality-control assessment and intraoperative
monitoring can virtually abolish the incidence of intraop-
erative stroke (apparent on recovery from anesthesia), the
incidence of stroke caused by postoperative thrombosis is
unaffected and complicates about 3% of CEAs.10 At reex-
ploration, these patients usually have friable platelet
thrombus adherent to the endarterectomy zone (rather
than to the patch), with no evidence of underlying techni-
cal error.8
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Table IV. Thirty-day morbidity and mortality
Dacron-patch Vein-patch
group group
(n = 137) (n = 139)
Cranial nerve injury
Mandibular branch of facial nerve 1 2
Hypoglossal nerve 3 2
Recurrent laryngeal nerve 2 2
Operative death
Acute cardiac failure 1 1
Brainstem stroke 0 1
Intracranial hemorrhage 0 1
Disabling stroke
MCA embolism 1 0
Cardioembolic* 0 1
Nondisabling stroke
Intracranial hemorrhage 0 1
MCA embolism 1 0
*After myocardial infarction, normal duplex and transcranial Doppler scan-
ning results.
MCA, Middle cerebral artery.
There is now evidence from three continents that
shows that patients destined to sustain a postoperative
stroke caused by carotid thrombosis have a preceding 1-
to 2-hour phase of increasing embolization.3-7 Despite the
high flow rates within the carotid artery, platelets start to
adhere to the endarterectomized surface within minutes of
flow restoration23 and serve as a source of ongoing
embolization and thrombus accumulation. In a recent
study of 500 patients who underwent CEA, as many as
70% of patients had one or more emboli detected in the
early postoperative period, but very high rates of sustained
embolization developed in only 5% of patients.2 Levi et al5
demonstrated that 60% of patients with high rates of post-
operative embolization will sustain a stroke. This is in
accordance with our own experience8 and consistent with
published data on the risk of postoperative carotid throm-
bosis. Embolization in this high-risk subgroup can be
abolished with incremental doses of intravenous dextran
40, which prevents progression to carotid thrombosis.11,12
Thus, the available evidence suggests that sustained post-
operative embolization is a high-risk predictor for pro-
gression to carotid thrombosis after CEA and that the rate
and magnitude of embolization could be used as an indi-
rect marker of a prothrombotic tendency.
The randomized trials to date have shown no system-
atic evidence that vein patches are safer than prosthetic
patches,1 and the findings of this latest study corroborate
this. This study has shown no evidence that the 30-day
operative risk is related to patch type. Similarly, patch type
had no influence on surgery time, drain losses, the need
for reexploration, neck wound pain, cranial nerve injury,
and the time of hospital discharge. Patients receiving a
vein patch inevitably had a higher incidence of groin
wound complications. No patient in this series sustained a
vein-patch rupture or prosthetic-patch infection. A meta-
analysis of a mix of nonrandomized and randomized trials
of vein patching versus synthetic patching concluded that
vein was superior with respect to recurrent stenosis and
possibly carotid thrombosis.24 This has not been corrobo-
rated by the Cochrane overview of randomized trials.1
These issues will be addressed in the long-term follow-up
of these patients.
Despite the findings of the overview of randomized
trials, there remains a perception among surgeons that
prosthetic patches are probably more thrombogenic than
vein patches. In the past, attempts to evaluate the throm-
botic nature of the carotid patch with isotope-labeled
platelets have been fraught with difficulty. This study is
the first to use the rate/magnitude of embolization as an
indirect marker of increased thrombotic potential relative
to patch type in a randomized trial. In preparation for
this study, we observed three factors that led us to
hypothesize that it may, paradoxically, be the patient who
is “prothrombotic” rather than the patch. First, patients
undergoing reexploration for postoperative stroke tend
to have thrombus accumulating on the endarterectomy
zone rather than on the patch, usually in the absence of
any underlying technical error.8 Second, it was observed
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that patients undergoing staged, bilateral CEAs had sim-
ilar rates of embolization after each procedure.25 Third,
we observed that although aspirin therapy had no influ-
ence on the rate of postoperative embolization, the
platelets of patients destined to have high rates of post-
operative embolization had an increased sensitivity to
adenosine diphosphate (ADP) stimulation.26
The results of this randomized trial have shown that
although Dacron patches were associated with a small but
significantly higher rate of embolization (median, 5 vs 3),
the difference was primarily evident in patients with the
lowest rates of postoperative embolization. In clinical
practice, such low rates of embolization have never been
associated with an increased risk of progressing to throm-
botic stroke. The incidence of detecting more than 50
emboli was almost identical for each patch type. More
important, the incidence of sustained high-rate emboliza-
tion requiring dextran therapy was unaffected by patch
type (6.6% for Dacron, 5% for vein).
However, two patients who received a Dacron patch
sustained ipsilateral embolic strokes despite adjuvant dex-
tran therapy. In one patient, adequate doses of dextran
could not be administered because of severe cardiac fail-
ure. In the second patient, dextran abolished the initial
phase of embolization, but the embolization recurred on
day 5. The latter is the only example of delayed reem-
bolization that was encountered in more than 650
patients. No occlusion or severe stenosis developed in
either patient at 30 days, suggesting that the embolic
phase was transient. These two cases suggest that dextran
may not be the perfect therapeutic agent for controlling
embolization in all high-risk patients, because there are
limitations in the patients in whom it can be used and also
in its need to be given intravenously. Alternatives to dex-
tran include Rheopro or S-nitrosoglutathione,27 but nei-
ther have been evaluated in large clinical series. However,
to put things in perspective, our policy of selective dextran
therapy has been associated with a 0.7% incidence of
embolic stroke for the study group as a whole, which is
significantly better than our experience before implement-
ing the protocol.2 Moreover, it has undoubtedly con-
tributed toward a 0% incidence of early postoperative
occlusion in 650 patients.
In summary, the findings of this study support the
hypothesis that prosthetic patches are as safe as vein
patches with regard to their thrombogenicity. Future
research must be directed at identifying why a small sub-
group of patients who undergo CEA appears to be at such
a high risk for the development of high-rate embolization,
thereby enabling other therapeutic strategies (eg, the pre-
operative administration of ADP antagonists) to be con-
sidered. This would not only make the surgery even safer,
but would clearly remove the need for any postoperative
TCD monitoring.
We thank the UK Stroke Association for its financial
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